Skip to main content

Table 1 Cohort characteristics

From: Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study

 

n (%)

Age (years)*

30.5 (± 18.7)

Sex

 Female

253 (59.7)

 Male

171 (40.3)

Length of stay (days)†

7 (4, 12)

Country of treatment

 Sierra Leone

290 (68.4)

 Liberia

134 (31.6)

Rapid diagnostic test for malaria results

 Positive

48 (11.3)

 Negative

195 (46.0)

 Not Tested

181 (42.7)

Cycle threshold value /viral load

 ≥22 (Low Viral Load)

122 (28.8)

  < 22 (High Viral Load)

159 (37.5)

 Missing

143 (33.7)

Treatments received in the first 48 hours of care

 Artemether-lumefantrine

376 (88.7)

 ORS

373 (88.0)

 Cefixime

360 (84.9)

 Multivitamins

261 (61.6)

 Ondansetron

111 (26.2)

 Vitamin C

383 (90.3)

 Zinc Sulphate

22 (5.2)

 Paracetamol

399 (94.1)

 Vitamin A

330 (77.8)

Signs & symptoms in the first 48 hours of care

 Abnormal Bleeding

122 (28.8)

 Coma

6 (1.4)

 Diarrhea

298 (70.3)

 Dysphagia

171 (40.3)

 Dyspnea

135 (31.8)

 Jaundice

25 (5.9)

 Anorexia

283 (66.7)

 Abdominal Pain

265 (62.5)

 Vomiting

254 (59.9)

  1. *Values represent mean with standard deviation
  2. †Values represent median with interquartile range